Home / David L. Joffe, BSPharm, CDE, FACA (page 6)

David L. Joffe, BSPharm, CDE, FACA

David L. Joffe, BSPharm, CDE, FACA
(Editor-in-Chief Diabetes In Control) A graduate of University of Kentucky College of Pharmacy, he has practiced in the Tampa Bay area since 1986, has been providing diabetes and cardiovascular care in Tampa Bay since 1995, and spent 2 years as an Eckerd Patient Care Pharmacist managing over 100 diabetes patients. Dave currently sees patients in over 30 primary care and endocrinologists offices.

Sept. 29, 2018

20 years ago when I was dispensing medications in a retail setting, it seemed like we handed out antibiotic prescriptions at least 50% of the time. This overuse without a reason often led to antibiotic resistance, and secondary a lot of yeast and fungal infections. Pharmacists often would recommend that …

Read More »

Sept. 25, 2018

According to medical references, Polycystic Ovary Syndrome (PCOS) is a group of symptoms due to elevated androgens in females. But what does that mean for your patients and their families, and why do we see an increased incidence at younger and younger ages? At the recent AACE meetings, our medical …

Read More »

Sept. 22, 2018

Way back in July of 2003, Steve and I attended the “Chromium in Health and Disease” summit in Boston. You have to remember that was when nutritional products were not so easily accepted by leading health care experts. This conference was somewhat remarkable in that there were “real” diabetes professionals talking about the use of …

Read More »

SGLT2 Inhibitors: A New Class of Diabetes Medications

SGLT2-1HIW

What is a SGLT2 Inhibitor? Sodium-glucose co-transporter 2 (SGLT2) inhibitors, also called gliflozin drugs,  are a new class of diabetic medications indicated for the treatment of type 2 diabetes. They have also been found to show cardiac benefits in patients with diabetes, and are being studied for possible use in type 1 diabetes. They work by reducing the absorption of glucose via the kidneys so that excess glucose is excreted through urination.

Read More »

Sept. 18, 2018

For years, we have often attributed the relative risk of developing diabetes to the heredity component. If your parents or grandparents had diabetes, there was a greater chance you would as well. Oftentimes patients use this as an excuse for *having* diabetes. Now that we have reasonably priced genetic testing …

Read More »

Sept 15, 2018

This week, our friends at Team Novo Nordisk, the only professional cycling team comprised of riders with type 1 diabetes, completed their most successful season. As many of you know, both myself and our publisher, Steve Freed, are avid cyclists and I am currently on track to hit 7,000 miles …

Read More »

Sep 13, 2018

The addition of mealtime insulin to a patient’s diabetes regimen can definitely increase the risk of hypoglycemia. This can be exacerbated if the patient is not counting carbs or doing before-meal glucose checks. This month in our special edition we look at the value of using an SGLT-2 Inhibitor instead …

Read More »

Sept. 11, 2018

The age-old question of which came first “the chicken or the egg” takes on new meaning this week in relation to what you can eat and, more importantly, in what order. Dr. Alpana Shukla, Assistant Professor, Weill Cornell Medicine, sat down with Joy Pape, our Medical Editor, at the recent ADA …

Read More »

Sept. 8, 2018

We depend on our interns to help us bring you the best in diabetes news and information, and a lot of times when I look at all they have to learn, it amazes me. There is so much more to being a pharmacist now than when Steve and I went …

Read More »

Sept. 4, 2018

A couple of weeks ago, I received an email from NSI, the National Stem Cell Institute, that contained their latest newsletter. This one focused on using adipose tissue-derived stem cells to repair meniscus tears. This caught my eye because three of my fellow cyclists had avoided surgery by having this procedure …

Read More »